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a b s t r a c t
Introduction: pyoderma gangrenosum (PG) is a rare and severe neutrophilic dermatosis asso-
ciated with inflammatory bowel disease (IBD) and other systemic diseases such as rheu-
matoid arthritis and hematological malignancies. Diagnosis is based on clinical criteria 
and exclusion of other skin disorders. There is no gold standard for the treatment of PG; 
traditionally intravenous corticosteroids are used, but recently the use of drugs that in-
hibit tumor necrosis factor alpha (TNF-alpha) has changed the management of PG, showing 
great effectiveness. 
Case report: female patient, 23 years old, diagnosed with severe nonspecific ulcerative colitis 
(UC) three years ago, undergoing treatment with oral mesalamine and azathioprine. She 
developed PG fourteen days after hospital discharge; hospitalization was due to worsening 
of intestinal disease symptoms. She was successfully treated using biological therapy after 
unfavorable evolution with corticosteroid therapy. 
Conclusion: PG, a rare extraintestinal manifestation of IBD of difficult resolution that has 
significant impact on patient quality of life. The use of biological therapy for PG has higher 
efficacy in the treatment of patients decreasing wound healing time and return to daily 
activities.
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r e s u m o
Terapia biológica no tratamento do pioderma gangrenoso   
Introdução: pioderma gangrenoso (PG) é uma rara e grave dermatose neutrofílica associada a 
doença inflamatória intestinal (DII) e a outras doenças sistêmicas como a artrite reumatoi-
de e neoplasias hematológicas. O diagnóstico é baseado em critérios clínicos e exclusão de 
outras desordens da pele. Ainda não há padrão ouro para o tratamento do PG, tradicional-
mente usa-se corticoides endovenosos, porém recentemente o uso de fármacos inibidores 
do fator de necrose tumoral alfa (TNF-alfa) tem mudado o manejo do PG mostrando grande 
efetividade.
© 2013 Elsevier Editora Ltda. Este é um artigo Open Access sob a licença de CC BY-NC-ND
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Introduction
Pyoderma gangrenosum (PG) is a rare neutrophilic dermatosis 
in which painful nodules and later pustules, due to subse-
quent necrosis of the dermis, open up to form irregular and 
painful, with a granular base, commonly with purplish and 
undermined borders.1 The lesions have distinctively an exu-
dative, mucopurulent content, often sterile and eventually 
hemorrhagic.1-2 
The lesions can be single or multiple, can appear in the site 
of prior trauma, but generally they affect the skin surround-
ing stomata and the extensor surface of the lower limbs and 
so they may be found in any part of the body. The anatomo-
pathological analysis shows evidence of nonspecific neutro-
philic dermatosis, however it has to be performed since PG 
diagnosis is based on clinical criteria and exclusion of other 
skin disorders.1-3 
This severe dermatosis appears in 1% to 2% of patients 
with inflammatory bowel disease (IBD) and its correlation 
with disease activity, although it seems to coincide with the 
intestinal disease exacerbation, especially in the colon, is 
still controversial as it also occurs independently. PG seems 
to be more common in ulcerative colitis (UC) than in Crohn’s 
disease (CD), occurring in approximately 5% of UC patients 
and just in 2% of those with CD.1,4-6 This dermatosis is also 
described in association to other systemic diseases such as 
rheumatoid arthritis, hematological malignancies and solid 
tumors, as well as in the idiopathic form.7-8
There is no gold standard for the treatment of PG and there 
is no evidence that show different results of treatment effec-
tiveness when it is intended for patients with or without IBD.1 
In general, immunosuppression is the mainstay of PG treat-
ment and intravenous corticosteroids have traditionally been 
the first-line treatment.1 Recently, the use of inhibitors of 
TNF-alpha has changed the management of PG in UC, show-
ing significant effectiveness.1 
In the present study we report a rare case of PG as extraint-
estinal manifestation of UC, successfully treated using biolog-
ical therapy after unfavorable evolution with corticosteroids. 
Case report
Female patient, 23 years old, Brazilian mulatto, a resident 
in the city of Cuiabá, state of Mato Grosso, Brazil, diagnosed 
with severe UC three years ago with involvement of the 
entire colon. She had been treated with oral mesalamine 
4 g/day since diagnosis and had also been using azathioprine 
2.5 mg/kg/day for the past year. She had a history of recurrent 
hospitalizations due to disease exacerbation, routinely 
treated with antibiotics and intravenous corticosteroids, 
followed by weaning and outpatient follow-up. She denied 
any extraintestinal manifestation of UC.
She sought treatment at the ER complaining of a non-
monitored fever, malaise, myalgia and multiple painful sores 
all over her body when she was hospitalized. She reported 
at the time of hospital admission, a previous 14 days hos-
pitalization due to the recent exacerbation of UC intestinal 
symptoms. At physical examination ulcers with undermined 
edges were observed with serosanguineous fluid and painful 
purplish pustules distributed over legs, ankles, and face (Fig. 
1). She denied any gastrointestinal symptoms at admission. 
Laboratory assessment showed: mild anemia, absence of leu-
kocytosis and elevated CRP (23.1 mg/dL). The patient declared 
that she had noticed the presence of small pustular lesions 
Relato do caso: paciente feminina, 23 anos, com diagnóstico de retocolite ulcerativa inespe-
cífica (RCUI) severa há três anos, em tratamento com mesalazina oral e azatioprina. Evoluiu 
apresentando PG quatorze dias após alta hospitalar, por internamento devido agudização 
dos sintomas intestinais da doença. Foi tratada com sucesso usando terapia biológica após 
evolução desfavorável com corticoide. 
Conclusão: PG, uma rara manifestação extraintestinal das DII, é de difícil resolução e com 
significante interferência na qualidade de vida dos pacientes. O uso de terapia biológica 
no PG vem mostrando melhor eficácia no tratamento desses doentes com diminuição do 
tempo de cicatrização das feridas e retorno às atividades diárias. 
© 2013 Elsevier Editora Ltda. 
Fig. 1 - Before starting treatment with IFX. Notice 
ulcers with undermined edges and necro hemorrhagic 
background.
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on the lower limbs and at previous venous puncture sites at 
the time of her last hospital discharge, but lent no importance 
to it. 
After admission, therapy with hydrocortisone 300 mg/day 
was promptly initiated, along with intravenous analgesics, 
and local care of the wounds with isotonic solution. Without 
significant response and with intense pain, on the third day 
of hospitalization it was decided to initiate biological therapy 
using Infliximab (IFX) at a dose of 5 mg/kg. After the first infu-
sion, at week 0, it was noted a significant decrease of the local 
inflammatory activity and the patient also reported an im-
portant decrease in localized pain. After the second infusion, 
at week 2, the lesions decreased in size and the epithelializa-
tion process could be noticed. After the third infusion at week 
6, the lesions showed almost complete re-epithelialization 
(Fig. 2) and after the fourth infusion at week 14, the lesions 
were at the advanced stages of healing with contraction of 
the edges (Fig. 3).
Even after completed treatment for PG, the patient con-
tinued using IFX regularly, which also resulted in a great 
impact on intestinal symptoms. Currently, she reports 1-2 
daily episodes of bowel movement without mucus, pus or 
blood.
Discussion
Although the etiology of PG is partially unknown, the skin 
damage does seem to be immune-mediated.1,3 Neutrophil 
dysfunction, together with defects in chemotaxis or hyperre-
activity have been suggested as possible causes.9 The goal of 
treatment is the rapid resolution of the lesions, as they may 
result in severe skin deformities.1 
Tumor Necrosis Factor-alpha (TNF-alpha) is a potent pro-
inflammatory cytokine present in patients with IBD and is 
reportedly expressed in skin samples from patients with PG; 
therefore, it is one of the key cytokines involved in this re-
sponse, as it contributes to the recruitment of inflammatory 
cells to the skin and increase the expression of adhesion mol-
ecules.10 
The safety, clinical effectiveness and capacity to reduce 
corticosteroid usage in patients with IBD undergoing therapy 
with IFX has been clearly proven by pivotal studies such as 
ACT 1, ACT 211 and SONIC.12 However, although the effective-
ness of IFX in PG lesions rapid healing has been described in 
recent case reports1,13-15 studies comparing the efficacy of IFX 
with other immunosuppressive drugs are still lacking.1 The 
largest multicenter, randomized, placebo-controlled trial in-
volving IFX in the treatment of refractory PG included 30 pa-
tients, 19 of which had a diagnosis of IBD and 6 of UC. After 
2 weeks, 46% of the IFX group showed improvement, in com-
parison to only 6% in the placebo group.16
Fig. 2 - After the third infusion of IFX. Ulcer is at the end 
of granulation phase, still reddish in appearance, showing 
almost complete epithelialization.
Fig. 3 - After the fourth infusion of IFX. Ulcer is shown 
at an advanced healing stage, with similar color to the 
surrounding skin, showing contraction of edges.
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Supported by the idea that the rapid and dramatic im-
provement of skin lesions is caused by the crucial role that 
TNF-alpha plays in the pathogenesis of PG, and that biologi-
cal drugs have been able to decrease the healing time of skin 
and mucosal lesions, thus allowing an earlier return to daily 
activities, it is reasoned that drugs that inhibit TNF-alpha may 
be a promising therapeutic strategy for PG in patients with 
UC, in which case they are being already used with significant 
efficacy. 
Conflicts of interest
The authors declare no conflicts of interest.
R e f e r e n c e s 
1. Van Assche G, Dignass A, Bokemeyer B, Danese S, Gionchetti 
P, Moser G, et al. Second European evidence-based consensus 
on the diagnosis and management of ulcerative colitis part 3: 
special situations. European Crohn’s and Colitis Organisation. 
J Crohns Colitis. 2013 Feb;7(1):1-33.
2. Callen JP. Pyodermagangrenosum. Lancet 1998; 351:581–585. 
3. Regueiro M, Valentine J, Plevy S, Fleisher MR, Lichtenstein 
GR. Infliximab for treatment of pyoderma gangrenosum 
associated with inflammatory bowel disease. Am J 
Gastroenterol 2003; 98: 1821–1826. 
4. Veloso RV. Review article: skin complications associated with 
inflamatory bowel disease. Aliment Pharmacol Ther 2004; 20 
(suppl. 4): 50-3.
5. Yuksel I, Basar O, Ataseven H, Ertugrul I, Arhan M, Ibis M, et 
al. N. Mucocutaneous manifestations in inflammatory bowel 
disease. Inflamm Bowel Dis; 2009; 15 (4): 546-50. 
6. Mir-Madjlessi SH, Taylor JS, Farmer RG. Clinical course and 
evolution of erythema nodosum and pyoderma gangrenosum 
in chronic ulcerative colitis: A study of 42 patients. Am J 
Gastroenterol 1985; 80(8): 615-20.  
7. Bennett ML, Jackson JM, Jorizzo JL, Fleischer AB Jr, White WL, 
Callen JP. Pyoderma gangrenosum: a comparison of typical 
and atypical forms with an emphasis on time to remission. 
Case review of 86 patients from 2 institutions. Medicine 
(Baltimore) 2000; 79:37-46. 
8. Hasselmann DO, Bens G, Tilgen W, Reichrath J. Pyoderma 
gangrenosum: clinical presentation and outcome in 18 cases 
and review of the literature. J Dtsch Dermatol Ges 2007;5:560-
564. 
9. Su WP, Davis MD, Weening RH, Powell FC, Perry HO. Pyoderma 
gangrenosum: clinicopathologic correlation and proposed 
diagnostic criteria. Int J Dermatol 2004;43:790-800.
10. Krueger JG. The immunologic basis for the treatment of 
psoriasis with new biologic agents. J Am Acad Dermatol 2002; 
46:1-23.
11. Reinisch W, Sandborn WJ, Rutgeerts P, Feagan BG, 
Rachmilewitz D, Hanauer SB, et al. Long-term infliximab 
maintenance therapy for ulcerative colitis: the ACT-1 and -2 
extension studies. Inflamm Bowel Dis. 2012 Feb;18(2):201-11.
12. Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, 
Kornbluth A, Rachmilewitz D, et al. Infliximab, azathioprine, 
or combination therapy for Crohn’s disease. N Engl J Med 
2010; 362:1383-1395.
13. Tan MH, Gordon M, Lebwohl O, George J, Lebwohl MG. 
Improvement of pyoderma gangrenosum and psoriasis 
associated with Crohn disease with anti-tumor necrosis 
factor monoclonal antibody. Arch Dermatol 2001;137: 
930–933.
14. Baglieri F, Scuderi G. Infliximab for treatment of resistant 
pyoderma gangrenosum associated with ulcerative colitis 
and psoriasis. A case report. Dermatol Ther 2010; 23: 541–543.
15. Del Giacco SR, Firinu D, Lorrai MM, Serusi L, Meleddu R, Barca 
MP, et al. Idiopathic Pyoderma Gangrenosum: Successful 
Resolution with Infliximab Therapy and Proinflammatory 
Cytokines Assessment. Acta Derm Venereol 1992. 
16. Brooklyn TN, Dunnill MG, Shetty A, Bowden JJ, Williams JD, 
Griffiths CE, et al. Infliximab for the treatment of pyoderma 
gangrenosum: a randomised, double blind, placebo controlled 
trial. Gut 2006; 55: 505–509.
